Type 2 diabetes took center stage in the days before the US Thanksgiving holiday as FDA approved two GLP-1 agonist/basal insulin combinations – Sanofi's Soliqua and Novo Nordisk AS's Xultophy – and received a submission from Intarcia Therapeutics Inc. for an implantable GLP-1 mini-pump. Here’s your news in brief:
FDA's Center for Drug Evaluation and Research (CDER) also approved a new indication for Janssen Biotech Inc. and





